What is the central role of plasminogen in the coagulation and fibrinolytic systems?

I. What are the basic characteristics of plasminogen?

Plasminogen is a serine protease precursor synthesized by the liver, with a plasma concentration of approximately 200 mg/L and a molecular weight of 92 kDa. This protein exists in two main forms in blood: glutamate-type plasminogen (Glu-PLG) with a half-life of about 2.2 days, and lysine-type plasminogen (Lys-PLG) with a half-life of about 0.8 days. As the inactive precursor of plasmin, plasminogen plays a key regulatory role in the coagulation-fibrinolysis balance.

Under physiological conditions, plasminogen is converted into active plasmin through a complex activation mechanism, primarily functioning to degrade fibrin clots and maintain vascular patency. However, the role of plasmin extends beyond this, as it can also degrade extracellular matrix components, participate in tissue remodeling processes, and activate various precursor proteins including hormones and cytokine precursors, demonstrating broad biological functions.

II. What is the position of the fibrinolytic system in coagulation regulation?

Blood coagulation and fibrinolysis are two opposing yet unified processes that maintain vascular homeostasis. The coagulation system forms fibrin clots through a cascade of reactions to prevent bleeding, while the fibrinolytic system is responsible for dissolving formed thrombi to maintain vascular patency. The precise balance between these two systems is crucial for maintaining normal physiological functions.

The fibrinolytic system mainly consists of plasminogen, plasminogen activators (including tissue-type tPA and urokinase-type uPA) and their inhibitors (primarily PAI-1). As the core component of this system, plasminogen activation primarily occurs on fibrin surfaces, a localization mechanism that ensures targeted and specific fibrinolytic activity. Plasmin generation is strictly regulated, requiring both activator promotion and inhibitor constraint, forming a sophisticated network of positive and negative feedback regulation.

III. What are the activation mechanism and functional characteristics of plasminogen?

The conversion of plasminogen to plasmin is mainly regulated by two types of activators: tissue-type plasminogen activator (tPA) primarily participates in fibrinolysis, while urokinase-type plasminogen activator (uPA) is more involved in non-fibrinolytic processes such as cell migration and tissue remodeling. On fibrin surfaces, tPA and plasminogen form a ternary complex, significantly improving activation efficiency, a mechanism that ensures spatial specificity and temporal controllability of the fibrinolytic process.

Activated plasmin has multiple biological functions. In addition to degrading fibrin, it can also break down various extracellular matrix proteins including fibronectin, laminin, and collagen, participating in tissue repair and remodeling processes. Furthermore, plasmin can activate various growth factor and cytokine precursors such as transforming growth factor-β and insulin-like growth factor, regulating cell proliferation and differentiation. Under certain pathological conditions, plasmin may also participate in tumor cell invasion and metastasis processes.

IV. What diseases are associated with plasminogen abnormalities?

Abnormal plasminogen levels are closely related to various disease states. Hereditary plasminogen deficiency is relatively rare, with patients often showing thrombophilia tendencies due to reduced fibrinolytic activity leading to increased thrombosis risk. These patients may experience recurrent venous thromboembolism and require long-term anticoagulation management.

Acquired plasminogen deficiency is more common, mainly seen in liver diseases and disseminated intravascular coagulation (DIC). Unlike hereditary deficiency, acquired deficiency is often accompanied by enhanced fibrinolytic activity, potentially causing bleeding tendencies. In liver disease patients, plasminogen levels typically decrease due to reduced synthetic function, while in DIC processes, excessive activation of the fibrinolytic system leads to consumptive reduction of plasminogen.

Notably, age also affects plasminogen levels. Full-term newborns have plasminogen concentrations about 50% of adult levels, gradually increasing to normal levels within six months after birth. Adult plasminogen levels are related to factors such as age, gender, and smoking habits, but are not affected by circadian rhythms or exercise.

V. What is the application value of Plasminogen recombinant rabbit mAb in related research?

Plasminogen recombinant rabbit monoclonal antibody, as a specific research tool for recognizing plasminogen protein, holds significant value in coagulation-fibrinolysis system research and clinical diagnosis. This antibody is prepared by immunizing New Zealand white rabbits, featuring high affinity and specificity, enabling accurate detection of plasminogen expression levels and distribution characteristics.

In basic research, this antibody can be used for protein expression analysis, quantitatively detecting plasminogen expression changes in different tissues or disease states through Western blot technology. Through immunohistochemistry, researchers can visualize plasminogen distribution patterns in tissues, understanding its localization characteristics in physiological and pathological processes. Additionally, this antibody can be used for immunoprecipitation experiments to study plasminogen's interaction networks with other proteins.

In clinical diagnostic applications, Plasminogen recombinant rabbit mAb can be used to establish sensitive detection methods for accurately measuring plasminogen concentration and activity in plasma. This is significant for diagnosing fibrinolytic system abnormalities, assessing thrombosis risk, and monitoring anticoagulation treatment effects. With the development of precision medicine, this antibody may also be used to develop personalized thrombosis risk assessment models to guide clinical treatment decisions.

VI. Which manufacturers provide Plasminogen recombinant rabbit monoclonal antibodies?

Hangzhou Start Biological Technology Co., Ltd. has independently developed "Plasminogen Recombinant Rabbit Monoclonal Antibody" (Product name: Plasminogen Recombinant Rabbit mAb (SDT-804-69), a high-specificity, excellent sensitivity and outstanding stability detection tool for key enzyme precursors in the fibrinolytic system. This product was developed using recombinant rabbit monoclonal antibody technology and has been strictly validated across multiple technical platforms including immunohistochemistry (IHC), Western Blot (WB) and ELISA, holding important application value in thrombosis and hemostasis research, tumor invasion and metastasis, and tissue repair fields.

Professional Technical Support: We provide detailed product technical materials, including staining characteristics in different pathological tissues, supplementary suggestions for detecting active and inactive forms, and professional technical consultation, fully assisting customers in making progress in vascular biology, oncology, and hemostasis and thrombosis research fields.

Hangzhou Start Biological Technology Co., Ltd. is always committed to providing high-quality, high-value biological reagents and solutions for global innovative pharmaceutical companies and research institutions. To learn more about

Product Information